Transcutaneous vagus nerve stimulation to enhance exposure efficacy in public speaking anxiety

eiden University Behandel en Expertise Centrum0 个研究点目标入组 52 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•A. Between 18-70 years old
•B. Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear.
•C. Self-reported SAD symptoms above clinical cut-off (score > 30 on the LSAS)

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•A. Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient’s report of receiving specific and regular exposure assignments as part of previous therapy.
•B. Prior participation in tVNS research
•C. Entry of patients with other mood or anxiety disorders will be permitted in order to increase accrual of a clinically relevant sample; however in cases where SAD is not judged to be the predominant disorder, participants will not be eligible.
•D. Psychosis or delusion disorders (current or in the past)
•E. Patients with significant suicidal ideations or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from participation and referred for appropriate clinical intervention.
•F. Mental retardation
•G. Substance or alcohol dependence
•H. Somatic illness (neurological and cardiac conditions)
•I. Pregnancy or lactation
•J. Antipsychotic medication
•K. Participants that use antidepressants or benzodiazepines will not be excluded, but have to be on a stable dose for at least 6 weeks prior to enrollment.
•L. Insufficient ability to speak and write Dutch

发起方

eiden University Behandel en Expertise Centrum